OSL Oncosil 0.7 cents $ 23 Million Market Cap , much lower Enterprise value after recent completion of CR
Strong team including some from Sirtex taken over $ 1.9 Billion , TLX Telix Pharmaceutical Limited , on its way to a $ 7 billion market cap. Has disappointed previously which is playing a role in the lackluster sp performance, but major changes to team since last year could change this.
Selling an actual device and are marketing, in trials and selling compared to some asx listed Biotechs in pre clinical or phase 1 studies with a similar or a higher market cap.
G-BA updates to come in the next quarter or so , R & D refund expected to be around $ 1 million and they have enough funds until end of next calendar , further expansion into markets, Sales , approvals , clinical trial updates , TGA , FDA , updates the stock price does not reflect any of this , sheesh have a look at the latest top 20 shareholder list.
Potential Take Over target. Back over a $100 million market cap to come.
